Xilonix ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 269 | Pyogenic arthritis | 1 |
269. Pyogenic arthritis
Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01965613 (ClinicalTrials.gov) | January 31, 2014 | 15/10/2013 | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Xilonix | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |